|
|
|
| Clinical effect of Oxaliplatin combined with chemotherapy for colorectal cancer |
| WU Hai-bo |
| Department of Interventional Oncology, Sujiatun Central Hospital of Shenyang City, Liaoning Province, Shenyang 110101, China |
|
|
|
|
Abstract Objective To investigate the clinical effect of Oxaliplatin combined with chemotherapy in the treatment of colorectal cancer.Methods A total of 120 patients with colorectal cancer admitted in our hospital from April 2018 to April 2019 were selected as subjects, and they were divided into the study group (n=78) and the control group (n=42).The patients in the control group were treated with chemotherapy and patients in the study group were treated with chemotherapy combined with Oxaliplatin.The treatment effect, adverse reactions, tumor necrosis factor-α (TNF-α), and interleukin-2 (IL-2) levels were compared between the two groups.Results The total effective rate of patients in the study group was higher than that in the control group, and the difference was statistically significant (P＜0.05).The total incidence of adverse reactions in the study group was lower than that in the control group, and the difference was statistically significant (P＜0.05).Before treatment, there was no significant difference in TNF-α and IL-2between the two groups (P＞0.05).After treatment, the TNF-α levels in both groups were lower than before treatment, and IL-2levels in both groups were higher than those before treatment, and the differences were statistically significant (P＜0.05).After treatment, TNF-α in the study group was lower than that in the control group, and IL-2was higher than that in the control group, with statistically significant differences (P＜0.05).Conclusion The combined application of Oxaliplatin and chemotherapy in the treatment of colorectal cancer can obviously improve the therapeutic effect and reduce the incidence of adverse reactions, which is worthy of application and promotion in various hospitals.
|
|
|
|
|
|
| [1] |
李旭丹，林铁强.雷替曲塞联合奥沙利铂方案二线治疗晚期结直肠癌的有效性和安全性分析[J].中国医药科学，2017，23（19）：246-249.
|
| [2] |
祝函函，郝永钟，丁胜文，等.奥沙利铂联合化疗治疗结肠癌的临床价值[J].深圳中西医结合杂志，2018，28（23）：177-178.
|
| [3] |
郭鲁伟，赵可，李科技，等.卡培他滨联合奥沙利铂新辅助化疗治疗局部进展期结直肠癌的效果和安全性分析[J].河南医学研究，2017，26（12）：2133-2135.
|
| [4] |
史曙霞.奥沙利铂联合卡培他滨与联合氟尿嘧啶化疗方案在老年晚期结肠癌治疗中的应用对比[J].医药论坛杂志，2018，39（10）：156-158.
|
| [5] |
唐瑶，吴永忠，陈晓品，等.替吉奥联合奥沙利铂一线治疗转移性结直肠癌有效性与安全性的Meta分析[J].临床肿瘤学杂志，2018，34（1）：52-60.
|
| [6] |
郭鲁伟，赵可，李科技，等.卡培他滨联合奥沙利铂新辅助化疗治疗局部进展期结直肠癌的效果和安全性分析[J].河南医学研究，2017，26（12）：2133-2135.
|
| [7] |
李红.伊立替康和奥沙利铂联合氟尿嘧啶类药物一线治疗晚期结直肠癌的效果观察[J].河南医学研究，2017，67（24）：4473-4474.
|
| [8] |
李想才.奥沙利铂联合卡培他滨治疗晚期直肠癌的疗效和安全性观察[J].临床医学工程，2018，25（8）：103-104.
|
| [9] |
潘新平.替吉奥联合奥沙利铂化疗方案治疗晚期胃癌的疗效分析及安全性[J].世界最新医学信息文摘，2017，23（1）：88.
|
| [10] |
易德京.奥沙利铂分别联合氟尿嘧啶与卡培他滨在转移性大肠癌的临床应用[J].当代医学，2018，45（2）：165-166.
|
| [11] |
左富义，于波，聂玉辉.替吉奥联合奥沙利铂与卡培他滨联合奥沙利铂方案治疗结直肠癌的疗效比较研究[J].中国全科医学，2017，20（29）：3612-3616.
|
| [12] |
吴驻林，谭婉君，潘沙沙，等.中药注射液联合含奥沙利铂化疗方案治疗大肠癌的网状Meta分析[J].中国实验方剂学杂志，2017，2（13）：211-219.
|
| [13] |
李慧，江旭，杨朝爱，等.动脉微泵灌注奥沙利铂治疗结直肠癌术后肝转移[J].中国介入影像与治疗学，2017，14（8）：455-459.
|
| [14] |
蔡月，邓儒，胡华斌，等.改良剂量的FOLFOXIRI 化疗方案（氟尿嘧啶、奥沙利铂、伊立替康）治疗结直肠癌的安全性和初步疗效分析[J].中华胃肠外科杂志，2018，21（9）：1045-1050.
|
| [15] |
刘俊宝，张弘纲，邵竹筠，等.雷替曲塞三线治疗转移性结直肠癌62例临床观察[J].中华肿瘤防治杂志，2018，25（4）：61-67.
|
| [16] |
孙翠玲，徐晓宇，高莹莹，等.奥沙利铂联合替吉奥治疗晚期结肠癌患者的临床疗效与安全性[J].中国临床药理学杂志，2017，33（16）：1540-1542.
|
|
|
|
